- Overstock.com, Inc. (OSTK) Stumbles After Reported Q3 2020 Financial Results
- What's the Analyst Recommendation for Rekor Systems Inc. (REKR)?
- Let’s Take a Look at Bunge Limited (BG) Stock
- Is it Time to Sell/Buy Callaway Golf Company (ELY) Stock After Recent Trade?
- Generac Holdings Inc. (GNRC) is up 115.84% this year
OncoCyte Corporation (OCX) share price soared 19.86% with the closing price of $1.75 on Wednesday. OncoCyte Corporation stock has an exchanging volume of 30.1 million shares, which is high, contrasted with its 3-months average volume of 821.33K shares. Its market capitalization has now reached to $117.69M.
Oncocyte Announces New Prospective Data Demonstrating That Treatment Informed by DetermaRx™ Significantly Improves Lung Cancer Patient Survival on October 14, 2020 at Yahoo.
Oncocyte Corporation (OCX) publicized that new prospective data on DetermaRx™ will be presented at the IASLC 2020 North America Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer. These data will be presented by Gavitt Woodard, M.D., Assistant Professor, Yale School of Medicine, and lead author on the study. DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (NSCLC) patients at high-risk of recurrence despite ostensibly curative surgery, who may benefit from the addition of chemotherapy. The test is reimbursed by Medicare and has seen rapid adoption in its first year of launch across seventy hospitals, including National Comprehensive Cancer Network (NCCN) and National Cancer Institute (NCI) cancer centers.
The Benchmark Company announced it was Reiterated coverage of OncoCyte Corporation in a research note on July 30, 2020. The analysts assigned a Speculative buy rating to the stock with a price target of $6. Piper Sandler rated the stock as a Neutral in a research noted published on July 01, 2020. Chardan Capital Markets rated the stock as a Neutral in a research note published on June 30, 2020.
Key takeaways include
Combining DetermaRx risk status with EGFR mutation status may help inform optimal treatment strategies for non-small cell lung cancer (NSCLC) patients who are EGFR-mutation-positive.
DetermaRx may inform the usage of chemotherapy, in addition to osimertinib, in the approximately 33% of EGFR positive patients who DetermaRx also identified as high-risk for cancer recurrence.
Given these data, Oncocyte will be offering EGFR mutation testing and DetermaRx on the same sample starting this quarter.
Results from the study will be discussed at a KOL webinar on October 22nd at 11:00 am PT led by Gavitt Woodard, M.D., Assistant Professor, Yale School of Medicine, cardiothoracic surgeon and lead author on the study, and David Gandara, M.D., Professor of Medicine Emeritus at the University of California, Davis, and Director of Thoracic Oncology at the UC Davis Comprehensive Cancer Center (UCDCCC).
OCX Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, OCX price has rose by 19.86%. In the course of past three months sees the stock go up around 23.24%, while it has lost -22.91% over the past six months and -22.22% since the start of the year.
OCX Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 143.0 million, which was higher than the gauge of 300k made by certain experts. For that equivalent quarter, OncoCyte Corporation posted -$0.14 earnings per share (EPS) which was underneath the consensus estimate of -$0.1 by -$0.04, which represents to a reduction by -40.00%.
OCX Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on OncoCyte Corporation has seen its stock exchanging -18.22% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +52.17% above its three-month low. A more extensive look sees OCX exchanging -50.14% beneath its 52-week high and 52.17% above from its 52-week low price.
OCX Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 10.85%, while it has a month to month instability of 10.22%. The company has an ATR (Average True Range) of 0.17 and a beta factor of 2.31.